HL23

Modify Date: 2024-09-23 12:17:34

HL23 Structure
HL23 structure
Common Name HL23
CAS Number 1448355-15-4 Molecular Weight 712.83
Density N/A Boiling Point N/A
Molecular Formula C44H44N2O7 Melting Point N/A
MSDS N/A Flash Point N/A

 Use of HL23


HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221)[1].

 Names

Name HL23

 HL23 Biological Activity

Description HL23 is a histone deacetylase (HDAC) inhibitor with activity against hepatocellular carcinoma (HCC). HL23 enhances acetylation of the TXNIP promoter and upregulates TXNIP expression, thereby mediating potassium channel activity and triggering TXNIP-dependent potassium deprivation. HL23 inhibits HCC progression and metastasis and has a synergistic effect with Sorafenib (HY-10201) and is more potent than Sorafenib+Vorinostat (HY-10221)[1].
Related Catalog
References

[1]. Lu Y, et al. Thioredoxin-interacting protein-activated intracellular potassium deprivation mediates the anti-tumour effect of a novel histone acetylation inhibitor HL23, a fangchinoline derivative, in human hepatocellular carcinoma. J Adv Res. 2023 Sep;51:181-196.. .  

 Chemical & Physical Properties

Molecular Formula C44H44N2O7
Molecular Weight 712.83